Abstract

Objectives: We have shown previously that human diabetic myocardium cannot be preconditioned. Here, we have investigated the basis of this cardioprotective deficit.

Methods: Right atrial sections from four patient groups–non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin–were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-KATP channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin. Cellular damage was assessed using creatine kinase leakage and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reduction. In mitochondrial preparations from non-diabetic and diabetic myocardium, mitochondrial membrane potential (Ψm) was assessed using JC-1 dye, and production of reactive oxygen species was determined.

Results: Preconditioning with ischemia, phenylephrine, adenosine, or diazoxide failed to protect diabetic myocardium. However, activation of PKC or p38MAPK was still protective. In isolated non-diabetic mitochondria, diazoxide partially depolarized Ψm, an effect not seen in diabetic mitochondria. Furthermore, diazoxide increased superoxide production in non-diabetic but not in diabetic mitochondria.

Conclusions: Our results show that the cardioprotective deficit in diabetic myocardium arises upstream of PKC and p38MAPK. We suggest that mitochondrial dysfunction in diabetic myocardium, possibly dysfunctional mito-KATP channels, leads to impaired depolarization and superoxide production, and that this causes the inability to respond to preconditioning.

1. Introduction

Preconditioning by a brief period of ischemia is a powerful cardioprotective intervention shown to occur in all animal species studied [1–5] and also in man [6–11]. We have recently shown that myocardium from patients with poor left ventricular function or with diabetes cannot be protected by preconditioning [12]. However, the myocardium from patients with poor left ventricular function can still be protected by the presumed mito-KATP channel (ATP sensitive mitochondrial potassium channel) opener diazoxide, whereas the diabetic myocardium cannot [12], supporting the view that the cause for the failure to cardioprotect the muscle is upstream of mito-KATP channels in the former and beyond this point in the latter. Other investigators have also reported that diabetes prevents preconditioning in patients with a first acute anterior wall myocardial infarction [13]. Several reasons have been suggested to explain the failure to precondition the diabetic myocardium, for example, anti-diabetic medication [14], hyperglycemia [15], or dysfunction of the sarcolemmal KATP channels [16,17]. It has been proposed that cardioprotection induced by opening mito-KATP channels involves the limitation of Ca2+ accumulation by mitochondrial depolarization [18,19], the preservation of mitochondrial inter-membrane architecture [20] and the generation of reactive oxygen species (ROS) [21]; however, the exact mechanism remains unclear. We have shown that mito-KATP channels are upstream of protein kinase C (PKC) and p38 mitogen-activated protein kinase (p38MAPK) in the signal transduction pathway of preconditioning [7] and it is possible that the failure to precondition the diabetic myocardium is due to alterations at any of these steps. It is generally accepted that ROS play a major role in ischaemic preconditioning (IPC) [21]. Superoxide radicals in particular has been shown to play a role in cardioprotection in non-diabetic myocardium [22], but in the diabetic myocardium, scavenging superoxide radicals was reported to be protective [23].

The objectives of the present study were to investigate the cause of the failure to precondition the human diabetic myocardium and to elucidate the underlying mechanism. We provide evidence that the cause of this failure is a dysfunction of the mitochondria with an alteration in the response of the mitochondrial membrane potential and production of superoxide in response to the mito-KATP channel opener diazoxide.

Methods

Study subjects

The study was conducted with patient consent and approved by the local ethics committee in accordance with the Helsinki declaration. Atrial biopsies were collected from patients undergoing elective coronary bypass surgery and/or aortic valve surgery prior to cardiopulmonary bypass. Three groups were included in the study, non-diabetic patients, insulin-dependent diabetes mellitus (IDDM) patients and non-insulin-dependent diabetes mellitus (NIDDM) patients. Patients on nicorandil, oral opioid or catecholemines or those with atrial fibrillation, poor left ventricular function (ejection fraction <30%) or right ventricular failure were excluded.

Processing of samples and experimental preparation

The study used an established model for quantification of the effect of ischemia and reperfusion on human cardiac muscle using thin slices of atrial appendages [24]. Briefly, sections (40 mg wet weight and 300–500 μm thick) were prepared from human right atrial appendage using a surgical skin-graft knife. Sections were immediately equilibrated in Krebs–Henseleit Hepes buffer (pH 7.4) containing (in mmol/l) NaCl2 (118), KCl (4.8), NaHCO3 (27.2), MgCl2 (1.2), KH2PO4 (1.0) CaCl2 (1.25), HEPES (20) and d-glucose (10) or 2-deoxy-d-glucose (10). The incubation medium was oxygenated by bubbling with 95% O2/5% CO2 maintained at 37 °C throughout the experiments. Simulated ischemia was induced by bubbling the medium with 95% N2/5% CO2 (pH 6.8–7.0) and replacing d-glucose with 2-deoxy-d-glucose as described previously [24]. The tissues were not electrically stimulated. IPC was induced by 5 min ischemia followed by 5 min reoxygenation, a protocol that has been shown in our laboratory to elicit optimal protection in this preparation [11].

Measurement of tissue injury and viability

Tissue injury was determined by measuring the leakage of creatine kinase (CK) into the incubation medium during the reoxygenation period using a CK-MB diagnostic kit (Sigma Diagnostics Catalogue No. DG147-K). In this assay CK catalyses the reaction between creatine phosphate and adenosine diphosphate (ADP) forming creatine and adenosine triphosphate (ATP). The ATP formed is utilized to phosphorylate glucose producing glucose-6-phosphate. Subsequently, glucose-6-phosphate is oxidized to 6-phosphogluconate in the presence of NADP. During this oxidation, an equimolar amount of NADP is reduced to NADPH resulting in an increase in absorbance at 340 nm. The rate of change in absorbance is proportional to CK activity and is expressed as U/g wet weight. Tissue viability was assessed by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to a blue formazan product at the end of the experimental time. The absorbance of the formazan formed was measured at 550 nm and the results were expressed as mmol formazan/g wet weight. The two indices were investigated to ascertain the degree of myocardial injury but it should be recognized that the MTT results might be influenced by the physiological state of the cell and the variance in mitochondrial dehydrogenase activity.

Mitochondrial isolation

Mitochondria were isolated from right atrial appendage tissue as follows. Myocardial sections were diced, incubated for 20 min in cold buffer at pH 7.4, containing (in mM) Hepes (10), mannitol (200), sucrose (70) and EGTA (1) and also trypsin at 0.25 mg/ml. Tissue sections were homogenized (Kontes Glass Co, New Jersey, USA) in ice-cold buffer without trypsin, and centrifuged for 10 min at 600 × g. The supernatant, containing the mitochondrial fraction, was centrifuged for 15 min at 11,000 × g, and the pellet was re-suspended in ice-cold storage buffer at a pH 7.4 containing (mM) Hepes (10), sucrose (250), ATP (1), ADP (0.08), sodium succinate (0.2), K2HPO4 (2) and DTT (1). The samples were assayed for protein concentration using a Biorad kit based on the Bradford dye-binding procedure [25] and the isolated mitochondria were used immediately.

Assessment of mitochondrial membrane potential (Ψm)

The mitochondria suspensions were diluted to 1 mg protein/ml in 20 mM MOPS buffer with pH 7.5 containing (in mM) KCl (110), ATP (10), MgCl2 (10), sodium succinate (10) and EGTA (1). Aliquots of mitochondria isolated from non-diabetics and diabetics, both insulin-dependent and NIDDM (8 patient per group, each patient yield 1 mitochondrial isolation), were randomized to receive one of the following protocols (n=8) for 10 min at 30 °C: (i) diazoxide (100 μM in DMSO); (ii) carrier alone (DMSO × 1%), (iii) or carboxyl cyanide m-chlorophenylhydrazone (CCCP, 1 μM), an uncoupler of the mitochondrial electron transport chain, as positive control. 2 μl of JC-1 (0.3mM) was added to 2 ml of diluted mitochondria suspension (between 10 and 50 μg protein) in 20 mM MOPS buffer pH 7.5. The fluorescence of each sample was then read at excitation wavelength of 490 nm and emission wavelength of 590 nm using a spectrofluorimeter. The MMP mean values were expressed as a percentage of the control (sample alone without diazoxide treatment). Fluorescence was excited at 490 nm and emission was read at 590 nm in a Fluostar spectrofluorimeter (BMG Labtech, Offenburg, Germany) [26]. JC-1 cationic fluorophore redistributes between the inside and outside of the mitochondrial matrix according to the membrane potential across the separating inner and outer membranes. Compounds that cause uncoupling of the mitochondria such as CCCP will show a drastic decrease in the JC-1 fluorescence due to the equalization of the JC-1 concentrations inside and outside the mitochondrial matrix. JC-1 was not used as a ratiometric indicator, as much information could be gained by studying the changes in the fluorescence of the individual wavelengths [27].

Cytochrome c measurements

Cytochrome c measurement was used to assess the quality of the isolated mitochondria. Cytochrome c oxidase is located on the inner mitochondrial membrane and it has been used as a marker for integrity of the outer membrane of the mitochondria [28–32]. Two parallel aliquots of mitochondrial suspension from non-diabetics, IDDM and NIDDM (6 patients/group, n=6), were diluted to 0.1–0.2 mg protein/ml in 5 mM Tris–HCl (pH7.4). N-Dodecyl β-d-maltoside (1 mM) was added to one aliquot of mitochondrial suspension to release the total cytochrome c oxidase activity (total activity). A parallel aliquot from the same mitochondrial suspension was used to measure the cytochrome c oxidase activity in the sample (intact mitochondria). Ferrocytochrome c (0.22 mM) was added to both aliquots and the release of ferrocytochrome c, which results in a decrease of the ferrocytochrome c absorbance, was quantified by spectrophotometry at 550 nm. The degree of mitochondria integrity were expressed as a percentage of the total cytochrome c oxidase activity subtracted by oxidase activity in intact mitochondria and divided by the total cytochrome c oxidase activity (cytochrome c oxidase assay kit–cytoc-ox1).

Electron microscopy

The presence of isolated mitochondria in the preparation was established using scanning electron microscopy.

Study protocols

  1. 1.

    To elucidate whether the intensity of the IPC stimulus influences cardioprotection in the diabetic myocardium: Myocardial sections obtained from diabetic patients (6 patients) were randomized to one of the following protocols (n=6/group); (i) simulated ischemia for 90 min and then reoxygenation for another 120 min; (ii) one or three cycles of IPC (5 min ischemia/5 min reoxygenation), followed by a period of 90 min ischemia and 120 min of reoxygenation; and (iii) time-matched aerobic controls. Tissue viability and damage were assessed by CK release and reduction of MTT at the end of the experimental protocol.

  2. 2.

    To investigate whether alterations in the signal transduction pathway of preconditioning are responsible for the failure to protect the diabetic myocardium: Myocardial tissue was obtained from patients without diabetes, with IDDM, with NIDDM on glibenclamide, and with NIDDM on metformin (12 patients/group). Right atrial appendages from these groups were randomly assigned (using the uniform discrete distribution, MiniTab Corp.) to one of the following protocols (n=8): (i) aerobic perfusion, (ii) simulated ischemia for 90 min then reoxygenation for another 120 min, and (iii) IPC or pharmacological preconditioning before simulated ischemia/reoxygenation. Pharmacological preconditioning was induced by phenylephrine (0.1 μM), adenosine (100 μM), diazoxide (mito-KATP channel opener at 100 μM), PMA (PKC agonist at 1 μM) or anisomycin (p38MAPK activator at 1 nM) each administered for 10 min before simulated ischemia/reoxygenation.

  3. 3.

    To investigate the effect of the mito-KATPchannel agonist diazoxide on the Ψmof diabetic myocardium: Aliquots of mitochondria isolated from non-diabetics and diabetics, both IDDM and NIDDM (8 patient per group, each patient yield 1 mitochondrial isolation), were randomized to receive one of the following protocols (n=8) for 10 min at 30 °C: (i) diazoxide (100 μM in DMSO); (ii) carrier alone (DMSO), (iii) or CCCP (1 μM) as positive control, at the end of which period Ψm was estimated.

  4. 4.

    To investigate the effect of diazoxide on superoxide generation by mitochondria from the diabetic myocardium: The effect of mito-KATP channel opening by diazoxide on superoxide generation in isolated mitochondrial preparations was performed as follows. Superoxide generation in isolated mitochondria was detected using the chemiluminescence of the probe lucigenin (15 μM) [33]. Diluted mitochondria suspensions isolated from right atrial myocardium of diabetics and non-diabetics (8 patients per group, each patient yield 1 mitochondrial isolation) were subjected to one of the following treatments (n=8) at 30 °C: superoxide generator xanthine (25 μM)/xanthine oxidase (0.01 U/ml) used as a positive control, diazoxide (100 μM), carrier only (DMSO 1%) and MnTBAP (2.4 μM) used as a negative control as it does not permeate the mitochondrial membrane. Mitochondrial samples were then loaded with chemiluminescence lucigenin and the production of superoxide was measured (Microlumat Plus LB 96 V, Berthold technologies, Germany). The peak relative luminescence per second (RLU/s) was used as an index of superoxide production and the results were expressed as percentage of the positive control.

  5. 5.

    To investigate the role of superoxide radicals on mitochondrial membrane depolarization by diazoxide: Aliquots of isolated mitochondria at equal protein concentration were obtained from non-diabetic myocardium and randomized to one of the following protocols for 10 min at 30 °C: (i) diazoxide (100 μM in DMSO), (ii) carrier alone (DMSO), (iii) diazoxide (100 μM) in combination with various concentrations of superoxide dismutase (200, 400 and 600 U/ml) [34], and CCCP (1 μM), used as positive control. Ψm was measured as described above.

Statistical analyses

All data are presented as mean ± S.E.M. Mean values were analyzed by a one-way ANOVA and paired Student's t-test where appropriate. p<0.05 was considered statistically significant.

Results

  1. 1.

    The effect of increasing the intensity of the IPC stimulus in the diabetic myocardium: As shown in Fig. 1A and B, IPC of diabetic myocardium with one cycle did not result in the reduction of CK leakage or in increase of MTT values when compared to those seen with SI/R alone. Increasing the intensity of the IPC stimulus to three cycles did not significantly alter the CK and MTT mean values obtained with SI/R alone (Fig. 1A and B). These results suggest that the failure to precondition diabetic myocardium does not depend on the intensity of the IPC stimulus. Similar results were obtained by our laboratory in the non-diabetic myocardium [11]. It should be clarified that the elevation in CK leakage seen in the aerobic control was probably due to the trauma caused by slicing the tissues.

    Fig. 1

    The effect of one and three cycles of IPC on CK leakage (A) and MTT reduction (B) in the diabetics' myocardium. Data are expressed as mean ± S.E.M. of n=6/group. A/C (aerobic/control), SI/R (simulated ischemia/reoxygenation).

    Fig. 1

    The effect of one and three cycles of IPC on CK leakage (A) and MTT reduction (B) in the diabetics' myocardium. Data are expressed as mean ± S.E.M. of n=6/group. A/C (aerobic/control), SI/R (simulated ischemia/reoxygenation).

  2. 2.

    Identification of the alteration in the signal transduction pathway of preconditioning responsible for the failure to protect diabetic myocardium: Fig. 2A and B shows that SI/R induces similar degrees of injury, as assessed by the CK leakage and MTT reduction, in the non-diabetic and diabetic groups, and that whereas IPC protected the non-diabetic muscles, it was ineffective in all forms of diabetes. Similarly, preconditioning with phenylephrine or adenosine resulted in equivalent protection to that of IPC in the groups without diabetes but failed to protect the diabetic groups. Importantly, the mito-KATP channel opener diazoxide protected non-diabetic myocardium but not the IDDM and NIDDM cardiac tissues; however, the PKC activator PMA and the p38MAPK activator anisomycin were equally protective in the diabetic and non-diabetic groups, a benefit that was similar to that obtained with IPC. The results in the IDDM groups were identical to those in the NIDDM groups independently of whether they were treated with glibenclamide or metformin. These results suggest that a dysfunction in the mito-KATP channel may be responsible for the failure to precondition diabetic human myocardium and that cardioprotection can still be obtained by the activation of PKC and p38MAPK. They also suggest that PKC and p38MAPK are downstream of mito-KATP channels in the signal transduction pathway of preconditioning, thus confirming our previous results in non-diabetic myocardium [7].

    Fig. 2

    The effect of ischemic (IPC) and pharmacological preconditioning on the creatine kinase (CK) leakage (A) and MTT reduction (B) in myocardium from non-diabetics and IDDM and NIDDM subjects treated with glibenclamide or with metformin. Phenylephrine (0.1 μM), adenosine (100 μM), diazoxide (100 μM), PMA (1 μM) or anisomycin (1 nM) each administered for 10 min before simulated ischemia/reoxygenation. Data are expressed as mean ± S.E.M. of n=6/group. *P<0.05 vs. preconditioning in the non-diabetic group. A/C: aerobic/control, SI/R: simulated ischemia/reoxygenation.

    Fig. 2

    The effect of ischemic (IPC) and pharmacological preconditioning on the creatine kinase (CK) leakage (A) and MTT reduction (B) in myocardium from non-diabetics and IDDM and NIDDM subjects treated with glibenclamide or with metformin. Phenylephrine (0.1 μM), adenosine (100 μM), diazoxide (100 μM), PMA (1 μM) or anisomycin (1 nM) each administered for 10 min before simulated ischemia/reoxygenation. Data are expressed as mean ± S.E.M. of n=6/group. *P<0.05 vs. preconditioning in the non-diabetic group. A/C: aerobic/control, SI/R: simulated ischemia/reoxygenation.

  3. 3.

    The effect of diabetes on Ψ m depolarization by diazoxide: As shown in Fig. 3, the Ψm, as detected by the fluorescence of JC-1, was decreased significantly by diazoxide in the non-diabetic myocardium but not in the IDDM and NIDDM groups, and as expected, the mitochondrial electron transport chain uncoupler CCCP fully depolarised the mitochondria in all three groups. The results on cytochrome c and electron microscopy (data not shown) demonstrated that more than 80% of the mitochondria were intact in our preparation.

    Fig. 3

    The effect of diazoxide on Ψm depolarization in isolated mitochondria from the myocardium of non-diabetic, IDDM, and NIDDM subjects. Data are expressed as a percentage of control (untreated groups). ± S.E.M. of n=8/group. *P<0.05 vs. control. CCCP, a known mitochondria uncoupler, was used as a positive control.

    Fig. 3

    The effect of diazoxide on Ψm depolarization in isolated mitochondria from the myocardium of non-diabetic, IDDM, and NIDDM subjects. Data are expressed as a percentage of control (untreated groups). ± S.E.M. of n=8/group. *P<0.05 vs. control. CCCP, a known mitochondria uncoupler, was used as a positive control.

  4. 4.

    The effect of diazoxide on superoxide generation by myocardial mitochondria: The superoxide generating system xanthine/xanthine oxidase produced similar chemiluminescence signals in the non-diabetic and diabetic groups and was used as a positive control. Fig. 4 shows that the chemiluminescence mean values, expressed as a percentage of the positive control, were slightly but significantly greater in the diabetic than in the non-diabetic groups. Interestingly, diazoxide significantly increased superoxide generation in the non-diabetic but not in the diabetic groups.

    Fig. 4

    The effect of diazoxide on superoxide generation by isolated mitochondria from the myocardium of non-diabetic, IDDM, and NIDDM subjects. MnTBAP was used as a negative control for superoxide generation. Data are expressed as a percentage of positive control ± S.E.M. of n=8 per group. *P<0.05 vs. non-diabetic corresponding group; +P<0.05 vs. the corresponding groups without diazoxide.

    Fig. 4

    The effect of diazoxide on superoxide generation by isolated mitochondria from the myocardium of non-diabetic, IDDM, and NIDDM subjects. MnTBAP was used as a negative control for superoxide generation. Data are expressed as a percentage of positive control ± S.E.M. of n=8 per group. *P<0.05 vs. non-diabetic corresponding group; +P<0.05 vs. the corresponding groups without diazoxide.

  5. 5.

    The role of superoxide radicals in Ψ m depolarization by diazoxide: Fig. 5 shows that the depolarization of Ψm by diazoxide was unaffected by the presence of SOD at various concentrations; this suggests that superoxide generation by the mitochondria of the non-diabetic myocardium does not influence Ψm depolarization, and that superoxide is produced beyond this point in the signal transduction pathway of preconditioning.

    Fig. 5

    The effect of superoxide scavenging with several concentrations of superoxide dismutase (SOD) on mitochondria membrane potential (Ψm) depolarization in isolated mitochondria from the myocardium of non-diabetics. Data are expressed as a percentage of control (untreated groups) ± S.E.M. of n=8 per group. CCCP, a known mitochondrial uncoupler, was used as positive control.

    Fig. 5

    The effect of superoxide scavenging with several concentrations of superoxide dismutase (SOD) on mitochondria membrane potential (Ψm) depolarization in isolated mitochondria from the myocardium of non-diabetics. Data are expressed as a percentage of control (untreated groups) ± S.E.M. of n=8 per group. CCCP, a known mitochondrial uncoupler, was used as positive control.

Discussion

In this study we show that diabetic human myocardium cannot be protected by preconditioning, when induced by ischemia or pharmacologically by phenylephrine, adenosine, or diazoxide. All of these treatments are effective in protecting non-diabetic myocardium. Preconditioning was ineffective whether tissue was obtained from patients with IDDM or from patients with NIDDM treated with either glibenclamide or metformin. In contrast, activation of either PKC or p38MAPK was able to protect diabetic tissue. We also found that mitochondria isolated from diabetic myocardium differed from those of non-diabetic tissue in two ways. First, whereas diazoxide partially depolarized non-diabetic mitochondria, it caused no depolarization of mitochondria from diabetic tissue. Second, diazoxide increased production of superoxide in mitochondria from non-diabetic but not from diabetic tissue. The inability of diazoxide to protect diabetic tissue, together with these alterations in mitochondrial response to diazoxide, suggests a mitochondrial dysfunction in diabetic tissue at the site(s) targeted by diazoxide, possibly the mito-KATP channel, while protective downstream kinase signaling pathways remain intact.

Diabetes and myocardial preconditioning

These studies showing that the diabetic human myocardium cannot be preconditioned by ischemia and diazoxide have confirmed previous results from our laboratory [12]; however, the effect of diabetes on preconditioning remains controversial in the literature. Thus, although other studies in man support the thesis that ischemic preconditioning fails to protect the diabetic myocardium [13,14], experimental animal studies have reported either no cardioprotection [15–17,35,36] or, on the contrary, greater protection [37,38] of preconditioning against ischemia in the diabetic heart compared to the non-diabetic. The reason for these discrepancies between human and animal studies and within animal studies is unclear, but it is possible that the animal model of streptozotocin-induced diabetes does not reflect entirely the clinical condition of diabetes and that the variable responses in animal models may depend on the duration of the pharmacologically induced diabetes [39].

An additional finding of our study is that the failure to precondition the diabetic myocardium could not be overcome by increasing the intensity of the preconditioning stimulus, since three cycles of ischemia did not afford protection. Antidiabetic medication itself can affect ischemic injury and this may be difficult to separate from the effects of diabetes. We [6], in the human myocardium, and other investigators in the dog [40] have shown that glibenclamide, a non-specific KATP channel blocker, abolishes the protection induced by ischemic preconditioning. Contrary to this, other medication received by diabetics may have opposite effects. Thus, insulin has been found to be cardioprotective by many investigators and metformin, a drug that has no effect on KATP channels, does not influence preconditioning or the tolerance to ischemia of the human myocardium (Hassouna and Galiñanes, unpublished results). The fact that the results in our studies were similar in all the diabetic groups, irrespective of the antidiabetic medication received, would suggest that diabetes per se is the cause of the failure to precondition the human myocardium. This hypothesis is supported by the finding that glimepiride does not block the cardioprotection of preconditioning in non-diabetic patients undergoing coronary angioplasty whereas those with diabetes cannot be preconditioned [41].

Are dysfunctional mito-KATP channels the cause of failure to precondition the diabetic myocardium?

The cardioprotective effect of diazoxide is generally considered to occur through an action on mitochondria and possibly by opening mito-KATP channels in the inner mitochondrial membrane [42–44]. It has been proposed that mito-KATP might induce protection by dissipation of the mitochondrial membrane potential with an uncoupling effect [43–45] that could lead to reduced mitochondrial Ca2+ loading during ischemia and reperfusion [46,47]. Holmuhamedov et al. [18] have reported that diazoxide and pinacidil depolarize cardiac mitochondria, reducing Ca2+ influx and accelerating Ca2+ efflux. Using isolated mitochondria preparation, we have clearly demonstrated that diazoxide causes partial depolarization of the mitochondria membrane potential in non-diabetics but not in diabetics. Therefore, we hypothesized that modest mitochondrial uncoupling may be a critical cellular event in orchestrating preconditioning.

The effect of diazoxide on the mitochondrial membrane potential in diabetic myocardium has not been reported previously and the reason why diazoxide depolarizes Ψm in non-diabetics but not in the diabetics is unknown. Experimental studies have shown that the Ψm of rat diabetic cardiomyocytes is slightly but significantly decreased from non-diabetic controls [48] and also that the Ψm of liver mitochondria from chronic diabetic rats has a lower value than normal mitochondria [49]. Therefore, it is possible that the Ψm is already depolarized in diabetics and that, as a result, diazoxide cannot act as a trigger for preconditioning. It is interesting to note that CCCP, which is a known mitochondria uncoupler, has a similar effect in diabetics and non-diabetics.

The involvement of the mito-KATP channel remains controversial, however, since diazoxide and other KATP channel openers can also have non-specific metabolic effects on mitochondrial function, in particular inhibition of succinate dehydrogenase, and it has been argued that this could also account for its cardioprotective effects [50–52]. Further, the mito-KATP blocker 5-hydoxydecanoate (5-HD) can also have metabolic effects. 5-HD can be activated to a CoA derivative and can then serve as a substrate in the β-oxidation pathway for fatty acids or, alternatively, depending on the isomer, inhibit this pathway [34,52]. It has been argued, therefore, that the effects of diazoxide and 5-HD in inducing and blocking IPC, respectively, may reflect actions on mitochondrial metabolism that do not necessarily involve mito-KATP channels [51–53]. Interestingly, inhibitors of succinate dehydrogenase such as diazoxide will inhibit the flow of electrons through the electron transport chain and are therefore likely to cause the production of ROS [54], while it has also been argued that mito-KATP opening leads to the production of ROS [21,55].

Reduced superoxide production in diabetic mitochondria

We found that diazoxide increases the production of superoxide radicals in non-diabetic but not in diabetic mitochondria. This lack of superoxide production in response to diazoxide may represent a key deficit in the response of the diabetic myocardium to preconditioning, since the generation of superoxide has been argued to be an important element of the signal transduction pathway of preconditioning [22,55]. Release of superoxide by co-infusion of hypoxanthine and xanthine oxidase elicits cardioprotection in the rabbit heart [22] while the superoxide scavenger MnTBAP abrogates ischemic protection in the guinea pig [56]. In isolated cardiac myocytes, hypoxia increases superoxide generation, which initiates preconditioning [57]. However, superoxide may not be the only ROS involved in preconditioning since both superoxide dismutase and the hydroxyl radical scavenger MPG attenuated cardioprotection by ischemic preconditioning in the rabbit heart [58] and MPG abolished diazoxide-induced protection in a human atrial-derived cell line [55].

Our results suggest that in the non-diabetic myocardium, diazoxide acts on mitochondria to cause generation of free radicals, especially superoxide, possibly as a result of Ψm depolarization. However, other studies reported that mild uncoupling may lead to a decrease in superoxide production [59]. Therefore, such an effect might result from opening of mito-KATP channels but could also result from respiratory chain inhibition by diazoxide. In either case, the mitochondrial target of diazoxide is dysfunctional in the diabetic myocardium, so that superoxide production is compromised and cardioprotection cannot be elicited.

Our findings also imply that preconditioning protection by ischemia itself, or by receptor activation with phenylephrine or adenosine stimuli, is also ineffective in diabetic tissue because of this dysfunction in mitochondrial superoxide production. However, the signal transduction pathway Ca2+ downstream of mitochondria remains intact in diabetic tissue, since activation of PKC or p38MAPK was still protective, confirming our previous findings from our laboratory [7]. These results suggest that mito-KATP channels are not the end effectors of preconditioning. The fact that activation of PKC may open the mito-KATP channels [60,61] should not be used as probe that these are the end effectors of preconditioning since we have recently observed that PKC ε is upstream and PKC α is downstream of mito-KATP[62].

Clinical implications and potential limitations

A major contribution of these studies is the demonstration that the failure to precondition the diabetic myocardium can be overcome by activation of the PKC and p38MAPK that are beyond the mito-KATP channels in the signal transduction pathway of preconditioning. However, since both PKC and p38MAPK have several isoforms and are involved in various biological processes, it would not be possible to use non-specific activators, similar to those utilized in the present studies, for clinical purposes. Because of this, it will be important to identify the specific PKC and p38MAPK isoforms involved in cardioprotection and to develop specific agents that would activate the relevant isoforms in order to elicit cardioprotection alone and spare other unwanted biological effects.

A potential limitation of our studies is the use of atrial tissue as opposed to ventricular myocardium, and because of this, any extrapolation must be conducted with caution. However, data from Yellon's laboratory [63] and our laboratory (unpublished data) have demonstrated that the response to ischemia/reoxygenation of ventricular and atrial tissue is similar. Another potential limitation is that data obtained in the isolated mitochondria may not necessary apply to the whole myocardial tissue and vice versa.

Acknowledgements

These studies were partly funded by a grant from Diabetes UK (RD01/0002329) and by a personal contribution from Professor Manuel Galiñanes. We acknowledge the secretarial assistance of Mrs. Nicola Harris.

References

[1]
Murry
C.E.
Jennings
R.B.
Reimer
K.A.
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium
Circulation
 
1986
74
1124
1136
[2]
Shiki
K.
Hearse
D.J.
Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias
Am J Physiol
 
1987
253
H1470
H1476
[3]
Schott
R.J.
Rohmann
S.
Braun
E.R.
Schaper
W.
Ischemic preconditioning reduces infarct size in swine myocardium
Circ Res
 
1990
66
1133
1142
[4]
Miller
D.L.
Van Winkle
D.M.
Ischemic preconditioning limits infarct size following regional ischemia–reperfusion in in situ mouse hearts
Cardiovasc Res
 
1999
42
680
684
[5]
Liu
G.S.
Thornton
J.
Van Winkle
D.M.
Stanley
A.W.
Olsson
R.A.
Downey
J.M.
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart
Circulation
 
1991
84
350
356
[6]
Ghosh
S.
Standen
N.B.
Galiñanes
M.
Evidence for mitochondrial K ATP channels as effectors of human myocardial preconditioning
Cardiovasc Res
 
2000
45
934
940
[7]
Loubani
M.
Galiñanes
M.
Pharmacological and ischemic preconditioning of the human myocardium: mitoK(ATP) channels are upstream and p38MAPK is downstream of PKC
BMC Physiol
 
2002
2
10
[8]
Speechly-Dick
M.E.
Grover
G.J.
Yellon
D.M.
Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model
Circ Res
 
1995
77
1030
1035
[9]
Yellon
D.M.
Alkhulaifi
A.M.
Pugsley
W.B.
Preconditioning the human myocardium
Lancet
 
1993
342
276
277
[10]
Ikonomidis
J.S.
Tumiati
L.C.
Weisel
R.D.
Mickle
D.A.
Li
R.K.
Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia
Cardiovasc Res
 
1994
28
1285
1291
[11]
Ghosh
S.
Standen
N.B.
Galiñanes
M.
Preconditioning the human myocardium by simulated ischemia: studies on the early and delayed protection
Cardiovasc Res
 
2000
45
339
350
[12]
Ghosh
S.
Standen
N.B.
Galiñanes
M.
Failure to precondition pathological human myocardium
J Am Coll Cardiol
 
2001
37
711
718
[13]
Ishihara
M.
Inoue
I.
Kawagoe
T.
Shimatani
Y.
Kurisu
S.
Nishioka
K.
et al
Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction
J Am Coll Cardiol
 
2001
38
1007
1011
[14]
Cleveland
J.C.
Jr.
Meldrum
D.R.
Cain
B.S.
Banerjee
A.
Harken
A.H.
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited
Circulation
 
1997
96
29
32
[15]
Kersten
J.R.
Montgomery
M.W.
Ghassemi
T.
Gross
E.R.
Toller
W.G.
Pagel
P.S.
et al
Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels
Am J Physiol Heart Circ Physiol
 
2001
280
H1744
H1750
[16]
del Valle
H.F.
Lascano
E.C.
Negroni
J.A.
Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels
Cardiovasc Res
 
2002
55
642
659
[17]
del Valle
H.F.
Lascano
E.C.
Negroni
J.A.
Crottogini
A.J.
Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction
Mol Cell Biochem
 
2003
249
21
30
[18]
Holmuhamedov
E.L.
Jovanovic
S.
Dzeja
P.P.
Jovanovic
A.
Terzic
A.
Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function
Am J Physiol
 
1998
275
H1567
H1576
[19]
Lopez
J.R.
Ghanbari
R.A.
Terzic
A.
A KATP channel opener protects cardiomyocytes from Ca2+ waves: a laser confocal microscopy study
Am J Physiol
 
1998
270
H1384
H1389
[20]
Dos Santos
P.
Kowaltowski
A.J.
Laclau
M.N.
Seetharaman
S.
Paucek
P.
Boudina
S.
et al
Mechanisms by which opening the mitochondrial ATP-sensitive K(+) channel protects the ischemic heart
Am J Physiol Heart Circ Physiol
 
2002
283
H284
H295
[21]
Pain
T.
Yang
X.M.
Critz
S.D.
Yue
Y.
Nakano
A.
Liu
G.S.
et al
Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals
Circ Res
 
2000
87
460
466
[22]
Baines
C.P.
Goto
M.
Downey
J.M.
Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium
J Mol Cell Cardiol
 
1997
29
207
216
[23]
Hayashi
T.
Mori
T.
Sohmiya
K.
Okada
Y.
Inamoto
S.
Okuda
N.
et al
Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus
J Cardiovasc Pharmacol
 
2003
41
923
929
[24]
Zhang
J.G.
Ghosh
S.
Ockleford
C.D.
Galiñanes
M.
Characterization of an in vitro model for the study of the short and prolonged effects of myocardial ischaemia and reperfusion in man
Clin Sci (Lond)
 
2000
99
443
453
[25]
Bradford
M.M.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal Biochem
 
1976
72
248
254
[26]
Reers
M.
Smiley
S.T.
Mottola-Hartshorn
C.
Chen
A.
Lin
M.
Chen
L.B.
Mitochondrial membrane potential monitored by JC-1 dye
Methods Enzymol
 
1995
260
406
417
[27]
Mathur
A.
Hong
Y.
Kemp
B.K.
Barrientos
A.A.
Erusalimsky
J.D.
Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes
Cardiovasc Res
 
2000
46
126
138
[28]
De Duve
C.
Tissue fractionation. Past and present
J Cell Biol
 
1971
50
20d
55d
[29]
Storrie
B.
Madden
E.A.
Isolation of subcellular organelles
Methods Enzymol
 
1990
182
203
225
[30]
Hovius
R.
Lambrechts
H.
Nicolay
K.
de Kruijff
B.
Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane
Biochim Biophys Acta
 
1990
1021
217
226
[31]
Rasmussen
U.F.
Rasmussen
H.N.
Human quadriceps muscle mitochondria: a functional characterization
Mol Cell Biochem
 
2000
208
37
44
[32]
Musatov
A.
Ortega-Lopez
J.
Robinson
N.C.
Detergent-solubilized bovine cytochrome c oxidase: dimerization depends on the amphiphilic environment
Biochemistry
 
2000
39
12996
13004
[33]
Stansbury
Li.Y.
Zhu
K.H.
Trush
H.
Biochemical characterization of lucigenin (bis-N-methylacridinium) as a chemiluminescent probe for detecting intramitochondrial superoxide anion radical production
Biochem Biophys Res Commun
 
1999
262
80
87
[34]
Hanley
P.J.
Gopalan
K.V.
Lareau
R.A.
Srivastava
D.K.
von Meltzer
M.
Daut
J.
Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels
J Physiol
 
2003
547
387
393
[35]
Kersten
J.R.
Toller
W.G.
Gross
E.R.
Pagel
P.S.
Warltier
D.C.
Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality
Am J Physiol Heart Circ Physiol
 
2000
278
H1218
H1224
[36]
Tosaki
A.
Pali
T.
Droy-Lefaix
M.T.
Effects of Ginkgo biloba extract and preconditioning on the diabetic rat myocardium
Diabetologia
 
1996
39
1255
1262
[37]
Tatsumi
T.
Matoba
S.
Kobara
M.
Keira
N.
Kawahara
A.
Tsuruyama
K.
et al
Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts
J Am Coll Cardiol
 
1998
31
707
715
[38]
Liu
Y.
Thornton
J.D.
Cohen
M.V.
Downey
J.M.
Schaffer
S.W.
Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction
Circulation
 
1993
88
1273
1278
[39]
Galiñanes
M.
Fowler
A.G.
Role of clinical pathologies in myocardial injury following ischaemia and reperfusion
Cardiovasc Res
 
2004
1
512
521
[40]
Gross
G.J.
Auchampach
J.A.
Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
Circ Res
 
1992
70
223
233
[41]
Lee
T.M.
Chou
T.F.
Impairment of myocardial protection in type 2 diabetic patients
J Clin Endocrinol Metab
 
2003
88
531
537
[42]
Garlid
K.D.
Paucek
P.
Yarov-Yarovoy
V.
Murray
H.N.
Darbenzio
R.B.
D'Alonzo
A.J.
et al
Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection
Circ Res
 
1997
81
1072
1082
[43]
Liu
Y.
Sato
T.
O'Rourke
B.
Marban
E.
Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?
Circulation
 
1998
97
2463
2469
[44]
Gross
G.J.
Peart
J.N.
KATP channels and myocardial preconditioning: an update
Am J Physiol Heart Circ Physiol
 
2003
285
H921
H930
[45]
Sato
T.
Sasaki
N.
O'Rourke
B.
Marban
E.
Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning?
Circulation
 
2000
102
800
805
[46]
Wang
L.
Cherednichenko
G.
Hernandez
L.
Halow
J.
Camacho
S.A.
Figueredo
V.
et al
Preconditioning limits mitochondrial Ca(2+) during ischemia in rat hearts: role of K(ATP) channels
Am J Physiol Heart Circ Physiol
 
2001
280
H2321
H2328
[47]
Murata
M.
Akao
M.
O'Rourke
B.
Marban
E.
Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection
Circ Res
 
2001
89
891
898
[48]
Tanaka
Y.
Konno
N.
Kako
K.J.
Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes
Cardiovasc Res
 
1992
26
409
414
[49]
Grinblat
L.
Bedetti
C.D.
Stoppani
A.O.
Calcium transport and energy coupling in diabetic rat liver mitochondria
Biochem Int
 
1988
17
329
335
[50]
Schafer
G.
Portenhauser
R.
Trolp
R.
Inhibition of mitochondrial metabolism by the diabetogenic thiadiazine diazoxide. I. Action on succinate dehydrogenase and TCA-cycle oxidations
Biochem Pharmacol
 
1971
20
1271
1780
[51]
Hanley
P.J.
Mickel
M.
Loffler
M.
Brandt
U.
Daut
J.
K(ATP) channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart
J Physiol
 
2002
542
735
741
[52]
Lim
K.H.
Javadov
S.A.
Das
M.
Clarke
S.J.
Suleiman
M.S.
Halestrap
A.P.
The effects of ischaemic preconditioning, diazoxide and 5-hydroxydecanoate on rat heart mitochondrial volume and respiration
J Physiol
 
2002
545
961
974
[53]
Das
M.
Parker
J.E.
Halestrap
A.P.
Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria
J Physiol
 
2003
547
893
902
[54]
Fleury
C.
Mignotte
B.
Vayssiere
J.L.
Mitochondrial reactive oxygen species in cell death signaling
Biochimie
 
2002
84
131
141
[55]
Carroll
R.
Gant
V.A.
Yellon
D.M.
Mitochondrial K(ATP) channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation
Cardiovasc Res
 
2001
51
691
700
[56]
Kevin
L.G.
Camara
A.K.
Riess
M.L.
Novalija
E.
Stowe
D.F.
Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion
Am J Physiol Heart Circ Physiol
 
2003
284
H566
H574
[57]
Vanden
Hoek T.L.
Becker
L.B.
Shao
Z.
Li
C.
Schumacker
P.T.
Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes
J Biol Chem
 
1998
273
18092
18098
[58]
Tanaka
M.
Fujiwara
H.
Yamasaki
K.
Sasayama
S.
Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit
Cardiovasc Res
 
1994
28
980
986
[59]
Miwa
S.
Brand
M.D.
Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling
Biochem Soc Trans
 
2003
31
1300
13001
[60]
Oldenburg
O.
Qin
Q.
Krieg
T.
Yang
X.M.
Philipp
S.
Critz
S.D.
et al
Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection
Am J Physiol Heart Circ Physiol
 
2004
286
H468
H476
[61]
Xu
Z.
Ji
X.
Boysen
P.G.
Exogenous nitric oxide generates ROS and induces cardioprotection: involvement of PKG, mitochondrial KATP channels, and ERK
Am J Physiol Heart Circ Physiol
 
2004
286
H1433
H1440
[62]
Hassouna
A.
Matata
B.M.
Galiñanes
M.
PKC-epsilon is upstream and PKC-alpha is downstream of mitoKATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium
Am J Physiol Cell Physiol
 
2004
287
C1418
C1425
[63]
Walker
D.M.
Walker
J.M.
Pugsley
W.B.
Pattison
C.W.
Yellon
D.M.
Preconditioning in isolated superfused human muscle
J Mol Cell Cardiol
 
1995
27
1349
1357

Author notes

Time for primary review 19 days